Cargando…

Effect of fecal microbial transplantation on Clostridioides difficile infection: dysbiosis, metabolites and health related quality of life

Detalles Bibliográficos
Autores principales:	Garey, Kevin W, Feuerstadt, Paul, Dubberke, Erik R, Guo, Amy, Tillotson, Glenn S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Insight Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036674/ https://www.ncbi.nlm.nih.gov/pubmed/36968968 http://dx.doi.org/10.1093/ofid/ofad113

Ejemplares similares

Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Clinical Trial
por: Garey, Kevin W, et al.
Publicado: (2023)

Role of the microbiome in essential metabolism in the human gut and its implications for Clostridioides difficile infection
por: Chopra, Teena, et al.
Publicado: (2023)

366. Association Between Gut Microbiota and Health-Related Quality of Life in Patients with Recurrent Clostridioides difficile Infection: Results from the PUNCH CD3 Clinical Trial
por: Feuerstadt, Paul, et al.
Publicado: (2023)

522. Significant Improvement in Health-Related Quality of Life (HRQL) with RBX2660: Results from a Phase 3 Randomized, Placebo-Controlled Trial in Recurrent Clostridioides Difficile Infection (PUNCH CD3)
por: Feuerstadt, Paul, et al.
Publicado: (2022)

Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
por: Orenstein, Robert, et al.
Publicado: (2023)

Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2023)

Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2021)

Safety of fecal microbiota, live-jslm (REBYOTA(™)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials
por: Lee, Christine, et al.
Publicado: (2023)

2235. Fecal Biomarkers for Clostridioides difficile Infection in Cancer Patients
por: Olvera, Adilene, et al.
Publicado: (2019)

Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis
por: Reveles, Kelly R., et al.
Publicado: (2023)

236. Treatment of Recurrent Clostridioides difficile Infection With RBX2660 in Patients ≥ 65 Years Old With Underlying Comorbidities
por: Tillotson, Glenn S, et al.
Publicado: (2022)

Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities
por: Tillotson, Glenn, et al.
Publicado: (2022)

Fecal microbiota transplantation beyond Clostridioides difficile infections
por: Wortelboer, Koen, et al.
Publicado: (2019)

Fecal Microbiota Transplantation beyond Clostridioides Difficile Infection
por: Moon, Chang Mo, et al.
Publicado: (2021)

Gut microbiota and microbiota-based therapies for Clostridioides difficile infection
por: Chopra, Teena, et al.
Publicado: (2023)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Transitions of care in Clostridioides difficile infection: a need of the hour
por: Khanna, Sahil, et al.
Publicado: (2022)

Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls
por: Sandhu, Avnish, et al.
Publicado: (2021)

Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites
por: Martinez-Gili, Laura, et al.
Publicado: (2020)

Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection
por: Chaar, Abdelkader, et al.
Publicado: (2021)

Gut Dysbiosis and Clostridioides difficile Infection in Neonates and Adults
por: Vasilescu, Iulia-Magdalena, et al.
Publicado: (2022)

Immunological mechanisms of fecal microbiota transplantation in recurrent Clostridioides difficile infection
por: Soveral, Lucas F, et al.
Publicado: (2022)

The Importance of a Broad Consortium of Bacteria for a Healthy Gastrointestinal tract: A Narrative Review of the Live Biotherapeutic Product REBYOTA
por: Tillotson, Glenn, et al.
Publicado: (2023)

Emerging Options for the Prevention and Management of Clostridioides difficile Infection
por: Gonzales-Luna, Anne J., et al.
Publicado: (2023)

Fecal Microbiota Transplantation for Clostridioides Difficile Infection in Patients with Chronic Liver Disease
por: Meighani, Alireza, et al.
Publicado: (2020)

Fecal Microbiota Transplantation Is Effective for the Treatment of Partially Treated Clostridioides difficile Infection
por: Cho, Young-Seok
Publicado: (2021)

Factors Related to Outcomes of Fecal Microbiota Transplantation in Patients with Clostridioides difficile Infection
por: Yoon, Hyuk, et al.
Publicado: (2021)

Ischemic colitis complicated by Clostridioides difficile infection treated with fecal microbiota transplantation
por: Kang, Seok Hyung, et al.
Publicado: (2023)

The microbial one-hit wonder
por: Rusconi, Brigida A., et al.
Publicado: (2021)

685. Early Experience with a Simple Administration of a Novel Fecal Microbiome Replacement for Prevention of Recurrent Clostridioides difficile
por: Hengel, Richard L, et al.
Publicado: (2023)

471. Prevalence and Characteristics of Clostridioides difficile Infection in Bangladesh
por: Sofjan, Amelia K, et al.
Publicado: (2018)

Lights, P450, action! Metabolite formation in chloroplasts
por: Warzecha, Heribert
Publicado: (2016)

752. Costs Attributable to Clostridioides difficile Infection in the Presence of Differential Mortality
por: Sahrmann, John, et al.
Publicado: (2021)

Deep hyperammonemic hepatic encephalopathy precipitated by fecal microbiota transplantation for fulminant Clostridioides difficile infection
por: Eriksen, Lotte Lindgreen, et al.
Publicado: (2021)

Clinical response and changes in the fecal microbiota and metabolite levels after fecal microbiota transplantation in patients with inflammatory bowel disease and recurrent Clostridioides difficile infection
por: Osaki, Hayato, et al.
Publicado: (2021)

2322: The effects of fecal microbiota transplantation on the gut microbiota in subjects with Clostridium difficile infection
por: Elizabeth Langdon, Amy, et al.
Publicado: (2018)

Fecal Microbiota of Toxigenic Clostridioides difficile-Associated Diarrhea
por: Hernández, Marta, et al.
Publicado: (2019)

Prevalence of Clostridioides difficile in Canine Feces and Its Association with Intestinal Dysbiosis
por: Werner, Melanie, et al.
Publicado: (2023)

Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA(TM)) Administered Under Enforcement Discretion to Patients With Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2023)

Faecalibacterium prausnitzii increases following fecal microbiota transplantation in recurrent Clostridioides difficile infection
por: Björkqvist, Olle, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ph0ija21tl7k86abk4am00pfso